AstraZeneca completed USD 2 billion deal: analysts target AstraZeneca stock at USD 206.67
Published on 10/13/2026 at 09:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS- AstraZeneca completed its USD 2.00 billion equity investment in Summit Therapeutics on October 5, 2026.
- MarketBeat reported an average one-year target of USD 206.67 from 18 analysts on October 12, 2026.
- AstraZeneca stock was trading at EUR 145.08 at Lang & Schwarz on October 13, 2026 at 9:43 a.m. CEST.
- Second-quarter revenue rose 6.40 percent year over year to USD 15.38 billion.
AstraZeneca (ISIN GB0009895292) completed its USD 2.00 billion equity investment in Summit Therapeutics on October 5, 2026, while MarketBeat reported on October 12, 2026 that 18 analysts placed the average one-year target at USD 206.67. The transaction expands AstraZeneca's oncology collaboration with Summit around ivonescimab and antibody drug conjugates.
Three milestones shape the deal
On September 28, 2026, AstraZeneca announced the USD 2.00 billion investment and a planned clinical collaboration with Summit. The agreement represented rights equivalent to 12.00 percent of Summit's outstanding common stock, or 10.60 percent on a fully diluted basis.
On October 5, 2026, AstraZeneca confirmed completion of the USD 2.00 billion investment. The collaboration is designed to combine ivonescimab with AstraZeneca cancer medicines across multiple tumor types.
On October 12, 2026, AstraZeneca's investor-relations calendar listed an ASBMR management event at 11:30 a.m. EDT. The date keeps the Summit transaction alongside a broader sequence of oncology and rare-disease updates.
What does the deal add?
The financial scale is clear, but the strategic point is access to a bispecific antibody that targets PD-1 and VEGF. AstraZeneca can test ivonescimab with sonesitatug vedotin and additional antibody drug conjugates, creating combination studies rather than a single-asset partnership.
The operating backdrop remains measurable. MarketBeat reported second-quarter revenue of USD 15.38 billion, up 6.40 percent year over year, while earnings per share reached USD 2.63 versus a USD 2.50 consensus estimate. That combination gives investors a current revenue-growth figure and a quantified earnings comparison.
Upcoming dates keep the pipeline active
AstraZeneca's investor-relations calendar lists an ESMO management event for October 26, 2026. Finanzen.ch reported that third-quarter 2026 results were expected on October 30, 2026. Those dates provide the next checkpoints for clinical progress and operating performance.
At Lang & Schwarz, AstraZeneca stock was trading at EUR 145.08 on October 13, 2026 at 9:43 a.m. CEST. The price is the current euro indication for investors in Germany and is separate from the USD analyst target and reporting figures.
The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.
AstraZeneca stock facts
- Company: AstraZeneca PLC
- ISIN: GB0009895292
- Ticker: AZN
- Primary exchange: LSE
- Price Lang & Schwarz as of October 13, 2026, 9:43 a.m. CEST: EUR 145.08
- Sector / Industry: Health care / Biopharmaceuticals
- Index membership: FTSE 100
Market context: Market report FTSE 100.
